Arecor Therape Regulatory News (AREC)

Arecor Therapeutics plc("Arecor" or the "Company")

Arecor and Sequel Med Tech to host virtual fireside panel discussion

· Key Opinion Leader commentary on the treatment journey for people with diabetes and factors driving future innovation

· Discussion around Arecor and Sequel's next generation insulin-AID system co-development deal; what's next for the future of the insulin/pump market

Cambridge, UK, 9 December 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on Wednesday 7 January at 16:00 GMT / 11:00 ET / 08:00 PT.

Speakers will include Dr Sarah Howell, CEO of Arecor, Dr Alan Lotvin, MD, CEO and Co-Founder of Sequel, and Thomas Blevins MD, FACE, FNLA, Endocrinologist and Key Opinion Leader on the Diabetes sector. The session will be chaired by Melanie Senior, Healthcare Writer and Analyst.

Topics to be discussed include the treatment journey for people with diabetes and the healthcare professional's experience; the current diabetes AID system market and the factors driving innovation; Arecor's AT278 ultra-concentrated, ultra-rapid insulin in development; Sequel's twiist device and its launch in the US; the next steps for both companies as they co-develop AT278 and the twiist device. Finally, a discussion about what's next for the diabetes / insulin pump sector; what are people with diabetes on intensive insulin therapy looking for in order to lower the daily management burden and improve outcomes. The session will conclude with a Q&A session.

To register for the event, please email arecor@vigoconsulting.com or Investors@SequelMedTech.com.

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.

About Sequel Med Tech

Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit www.sequelmedtech.com.